Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:08:32 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Q:AGIO - AGIOS PHARMACEUTICALS INC - http://www.agios.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AGIO - Q9.929.28·31.217.529.53+0.100.3747.421,6677,04629.27  30.28  28.7135.50  19.79516:20:00Apr 1815 min RT 2¢

Recent Trades - Last 10 of 7046
Time ETExPriceChangeVolume
16:20:00Q29.530.1063
16:04:47Q29.530.1095
16:04:45Q29.530.10400
16:04:44Q29.530.102,718
16:04:43Q29.530.10165
16:04:40Q29.530.10921
16:04:37Q29.530.10211
16:04:36Q29.530.1082
16:04:25Q29.530.10396
16:04:23Q29.530.10596

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 07:00U:AGIONews ReleaseAgios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
2024-04-09 07:00U:AGIONews ReleaseAgios Publishes 2024 Environmental, Social and Governance (ESG) Report
2024-03-05 07:00U:AGIONews ReleaseAgios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
2024-02-22 07:00U:AGIONews ReleaseAgios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
2024-02-15 07:00U:AGIONews ReleaseAgios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
2024-02-02 07:00U:AGIONews ReleaseAgios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
2024-01-08 07:00U:AGIONews ReleaseAgios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
2024-01-03 06:30U:AGIONews ReleaseAgios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
2024-01-02 07:00U:AGIONews ReleaseAgios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
2023-12-09 19:00U:AGIONews ReleaseAgios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
2023-11-20 07:00U:AGIONews ReleaseAgios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
2023-11-02 09:05U:AGIONews ReleaseAgios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
2023-11-02 07:00U:AGIONews ReleaseAgios Reports Business Highlights and Third Quarter 2023 Financial Results
2023-10-19 07:00U:AGIONews ReleaseAgios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
2023-08-29 07:00U:AGIONews ReleaseAgios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
2023-08-03 06:35U:AGIONews ReleaseAgios Reports Business Highlights and Second Quarter 2023 Financial Results
2023-08-03 06:30U:AGIONews ReleaseAgios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
2023-07-13 07:00U:AGIONews ReleaseAgios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
2023-06-26 06:30U:AGIONews ReleaseAgios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
2023-06-05 07:00U:AGIONews ReleaseAgios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023